Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates
New mechanism identified behind blindness in older adults
12 April 2021THC and CBD content on labels of medicinal cannabis products may not be accurate
12 April 2021Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates
A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using precision therapy targeting of cell-surface proteins through a Bicycle toxin conjugate (BTC), shows encouraging results for the treatment of osteosarcoma.
